Currently, ICIs are only approved for PD-L1 positive immune infiltrated TNBCs in combination with the chemotherapeutic nab-paclitaxel; however, increased tumor immunogenicity via MEKi pretreatment could lead to increased ICI efficacy in TNBCs. The gene discussed is CD274; the disease is neoplasm.